Study to Evaluate a Contact Lens Lubricating and Rewetting Drop

Not Applicable

Completed

Interventions: Device: Lubricating and Rewetting Drops
Device: AMO Blink Contacts Lubricant Eye Drops

Brief Summary: The objective of this study is to evaluate the product performance of investigational lubricating and rewetting drops.

Recruitment & Eligibility

Inclusion Criteria

Have physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings.
Adapted wearers of soft contact lenses, wear a lens in each eye, and each lens must be of the same manufacture and brand.
Use a lens care system on a regular basis.
Wear their habitual lenses (or be willing to wear lenses) a minimum of 8 hours per day.
Willing to use drops 4 times per day.

Exclusion Criteria

Participating in a conflicting study.
An active ocular disease, any corneal infiltrative response, or are using any ocular medications.
Any scar or neovascularization within the central 4mm of the cornea.
Any grade 2 or greater finding during the slit lamp examination
Using any systemic or topical medications that will affect ocular physiology or lens performance.
Aphakic.
Amblyopic.
Allergic to any component in the study care products.
Have had any corneal surgery.

Arm && Interventions

Group	Intervention	Description
Lubricating and Rewetting Drops	Lubricating and Rewetting Drops	Lubricating and Rewetting Drops, after one week of using the first rewetting drops, the subjects will return for an exam and crossover to the second rewetting drops for one week.
AMO Blink Contacts Lubricant Eye Drops	AMO Blink Contacts Lubricant Eye Drops	AMO Blink Contacts Lubricant Eye Drops, After one week of using the first rewetting drops, the subjects will return for an exam and crossover to the second rewetting drops for one week

Primary Outcome Measures

Name	Time	Method
Percentage of Eyes With Graded Slit Lamp Findings Greater Than Grade 2.	At 1 week follow up	Slit lamp findings for epithelial edema, epithelial microcysts, corneal staining, limbal injection, bulbar injection, upper lid tarsal conjunctival abnormalities, corneal neovascularization, and corneal infiltrates were graded 0 to 4, with 0 = none to 4 = severe. The outcome measure is any finding \> grade 2, across abnormalities.

Secondary Outcome Measures